Bonus Material-Cystic Fibrosis

Video Transcription

Video Summary

Holly Keat from the University of Texas Health in San Antonio presented a board review on cystic fibrosis, focusing on epidemiology, pathophysiology, diagnosis, management, and complications. Cystic fibrosis is a rare genetic disease affecting about 30,000 people in the US and 100,000 worldwide, most prevalent in North America, Europe, and Australia. The disease is caused by mutations in the CFTR gene on chromosome 7, leading to defective chloride transport. Diagnosis includes newborn screening and genetic testing. Management involves a multidisciplinary approach, including CFTR modulator therapies like ivacaftor and tezacaftor, targeting specific mutations like Delta F508. Common complications include exacerbations, hemoptysis, pneumothorax, infections such as aspergillus and NTM, and advanced lung disease. Treatment strategies, such as bronchodilators, airway clearance, and antibiotics, aim to improve lung function and quality of life. Advanced lung disease may necessitate lung transplant evaluation. The advent of CFTR modulators has significantly improved survival and reduced the need for lung transplants in patients with cystic fibrosis.

Meta Tag

ABIM blueprint - Pulmonary Obstructive Lung Disease

Concept Cystic Fibrosis

Concept CFTR Chloride Channel

Concept Sweat Chloride Test

Concept Pulmonary Exacerbation

Concept CFTR Mutation

Curriculum Category Obstructive Lung Disease

Faculty Holly L. Keyt, MD, FCCP

Keywords

cystic fibrosis

CF

CFTR gene

genetic testing

CFTR modulators

Delta F508

lung transplant

airway clearance

Obstructive Lung Disease

Cystic Fibrosis

CFTR Chloride Channel

Sweat Chloride Test

Pulmonary Exacerbation

CFTR Mutation

Holly L. Keyt, MD, FCCP

OLD